Notes

We found that this vaccine elicited strong binding and neutralizing antibody responses against homologous virus
We also observed broad binding antibody against heterologous contemporary and ancestral strains, but neutralizing antibody responses were primarily targeted to the vaccine-homologous strain. While binding antibody responses were sustained, neutralizing antibody waned to undetectable levels in some animals after six months but were rapidly recalled and conferred protection from disease when the animals were challenged 7 months after vaccination as evident by reduced viral replication and pathology in the lower respiratory tract, reduced viral shedding in the nasal cavity and lower concentrations of pro-inflammatory cytokines in the lung. Cumulatively, our data demonstrate in pigtail macaques that a self-amplifying replicon RNA vaccine can elicit durable and protective immunity to SARS-CoV-2 infection. Furthermore, these data provide evidence that this vaccine can provide durable protective efficacy and reduce viral shedding even after neutralizing antibody responses have waned to freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Institute of Allergy and Infectious Diseases, National Institutes of Health, Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Institute of Allergy and Infectious Diseases, National Institutes of Health, Institute of Allergy and Infectious Diseases, National Institutes of Health, Institute of Allergy and Infectious Diseases, National Institutes of Health, Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain following competing interests: JHE, APK, JA, and DHF have equity interest in HDT Bio Corp.

JHE and APK are inventors on granted U.S. patents pertaining to HDT Bio’s proprietary cationic nanocarrier formulation. JHE and DHF have current or previous consulting agreements with various life sciences companies. All other authors declare that they have no competing interests.time to revise vaccination strategies.transplant patients, and effective vaccination is aimed to reduce severe disease and mortality.

METHODS: We conducted a cross-sectional study to evaluate humoral and cellular response to two 4-μg doses of BBIBP-CorV vaccine in 100 kidney transplant recipients, using anti-spike IgG, total anti-receptor-binding domain, neutralizing antibody (Ab) level (enzyme-linked immunoassay), and interferon-gamma release assay (IGRA). RESULTS: vitamin d3 was evaluated 85.84 ± 30.72 days after the second dose. Note that, 58% of all and 43.05% of infection-naïve participants have developed at least one of the tested antibodies. IGRA was positive in 30.

7% of tested transplant recipients. Sixty percent of the participants had either humoral or cellular responses to COVID-19. Only age was independently linked to seropositivity of any degree after vaccination (p < .05). COVID-naïve patients older than 60 years developed significantly less neutralizing Abs. (p = .011).

Six patients developed mild COVID infection more than a month after the second dose of the vaccine (54.5 ± 20.8 days). No vaccine-related adverse effects were reported, except self-limited mild to moderate fever and injection site pain. CONCLUSION: BBIBP-CorV vaccine can be used safely in kidney transplant recipients, although impaired cellular and humoral immunity necessitate adjustments in vaccination strategies, like higher (8-μg doses), fourth booster dose, or boost with different platform patients with solid neoplasms under active treatment.2019 (COVID-19) infection. Knowledge regarding the efficacy of the messenger RNA (mRNA) vaccines in actively treated cancer patients is limited as they had been excluded from the pivotal studies of these vaccines.

We evaluated humoral and cellular immune responses in cancer patients after double vaccination and a booster dose and identified disease- and treatment-related factors associated with a reduced immune response. vitamin d3 documented the number and outcome of breakthrough infections.
My Website: https://en.wikipedia.org/wiki/Vitamin_D